



Cannabis use preferences in women with myofascial pelvic pain: A cross-sectional study

Emily C. Yang^{a,*}, Nicole A. Koenig^a, Merry Gong^a, Lori A. Brotto^a, Alasdair M. Barr^a, Terry Lee^b, Paul J. Yong^a, Roxana Geoffrion^a

^a University of British Columbia, Vancouver, BC, Canada

^b Centre for Health Evaluation & Outcome Sciences, Vancouver, BC, Canada

ARTICLE INFO

Keywords:

Myofascial pelvic pain
Chronic pelvic pain
Cannabis
Vaginal suppository
Vulvar cream

ABSTRACT

Objective: Myofascial tenderness is present in most chronic pelvic pain conditions and causes significant distress to patients. Treatment is challenging and often not curative. Cannabis is often used for self-management of chronic pelvic pain. However, we do not know which concentrations and routes of administration are most acceptable to users. We aimed to investigate patterns and willingness of cannabis product use among both habitual users and non-users with myofascial pelvic pain (MPP), to inform therapeutic development.

Study design: We conducted a cross-sectional study of questionnaire responses from female patients with MPP from two tertiary pelvic pain centers. We aimed for a convenience sample of 100 responses with representation from both centers. Inclusion criteria were age over 18 with pelvic floor muscle tenderness on standard gynecologic examination. We collected information on demographics, pelvic pain history, cannabis use status, cannabis use preferences, validated opioid misuse risk assessment, and interest in using gynecologic cannabis products and used descriptive analyses.

Results: 77/135 (57 %) questionnaire respondents were cannabis users and 58 (43 %) were non-users. Most users consume cannabis daily, (48.1 %) orally (66.2 %) or by smoking (60.7 %), and rated cannabis as effective at relieving pelvic pain. 37/58 (63.8 %) non-cannabis users responded that they would be willing to use cannabis for pelvic pain. Lack of information and potential adverse effects were the most common reasons for unwillingness to use. Approximately 3 of 4 respondents were willing to try vaginal or vulvar application of cannabis products for pelvic pain.

Conclusions: This cross-sectional study describes cannabis use patterns in MPP patients. Topical vulvar and vaginal cannabis products are of strong interest to both cannabis users and non-users and warrant further research.

1. Introduction

Pelvic pain is associated with impaired functioning in all facets of life from poor sleep, potential analgesic dependency, to medical and financial burdens [1,2]. Within pelvic pain, myofascial pelvic pain (MPP) is an important but commonly overlooked contributor [3]. MPP affects 22–94% of patients with chronic pelvic pain [4]. It is characterized by the presence of painful trigger points in pelvic floor musculature and connective tissue, and is typically associated with allodynia and hyperalgesia [3,5]. A validated, standardized technique for MPP

examination now exists which will hopefully improve routine recognition and targeted treatment [6].

Treatment for MPP is difficult, often requiring a combination of synergistic therapies [2]. Current treatments include nonsteroidal anti-inflammatories, muscles relaxants, neuromodulators, and pelvic floor physical therapy [7]. Opioid analgesics and trigger point injections, with or without botulinum toxin, can also be used [8]. MPP is frequently refractory to common treatments because of the concurrent myofascial component, central sensitization, and chronic inflammation [9]. Novel therapies are greatly needed.

Abbreviations: MPP, Myofascial pelvic pain; SOAPP, Screener and Opioid Assessment for Patients with Pain; CCS, Canadian Cannabis Survey; CBD, Cannabidiol; THC, Delta-9-tetrahydrocannabinol.

* Correspondence to: St. Paul's Hospital, Department of Obstetrics and Gynecology, Suite 930, 1125 Howe Street, Vancouver, BC, Canada V6Z 2K8.

E-mail address: ecyang@student.ubc.ca (E.C. Yang).

<https://doi.org/10.1016/j.eurox.2023.100192>

Received 12 May 2022; Received in revised form 2 March 2023; Accepted 29 March 2023

Available online 30 March 2023

2590-1613/Crown Copyright © 2023 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. A. Recruitment and data collection flowchart.

Cannabis use is increasing and self-medicating is common for the treatment of pain [10]. Meta-analysis results show that smoked cannabis, oromucosal cannabis sprays and oral cannabinoids all significantly reduced chronic, non-cancer pain compared to placebo without increased risk of serious adverse events [11]. Legalization of cannabis in Canada in 2012 increased use by 8.2 % in patients with chronic pelvic pain, and we showed that one in five female patients use cannabis products for relief [12]. Over half of patients who have never used cannabis expressed willingness to use it for gynecological pain [13]. Although recent surveys show almost nine of ten women are willing to consider being in a clinical trial of medical cannabis to treat chronic pelvic pain, it is unclear which products should be used, at what concentration, and through which route [14]. We aimed to recruit cannabis users and non-users with MPP to determine details of current products used as well as willingness to use potential topical products such as vaginal inserts. The goal was to inform further research and development of new treatments for myofascial chronic pelvic pain.

2. Material and methods

Our descriptive cross-sectional study was approved by local institutional research ethics boards (#H20-01959). We wrote a detailed questionnaire in consultation with a pharmacology expert (AB) and a clinical psychologist (LB) (Appendix A). Cannabis users were defined as participants currently using cannabis for any medical or recreational reasons. Non-users were participants not currently using cannabis for any reason.

We recruited female patients with MPP from two tertiary pelvic pain centers. Inclusion criteria were patients over age 18 with recorded tenderness in at least one of the right or left levator ani or obturator internus muscles during gynecologic examination. We excluded patients not fluent in English. We used slightly different recruitment methods at each of the two sites. Clinic 1 had an existing registry (EPPIC; ClinTrials.gov #NCT02911090) of pelvic pain patients [14]. Emails containing a cover letter explaining the research study and a private link for the questionnaire were sent to patients who had consented for research participation. Clinic 1 has a focus on MPP due to endometriosis. Clinic 2 did not have an existing registry. We identified patients with MPP using ICD codes on chart review and mailed invitation letters, then followed

up with a phone call and collected email addresses from those interested in participating. Clinic 2 has a focus on MPP due to urogynecologic concerns.

From both centers, we aimed for a total convenience sample of 100 complete questionnaire responses. Given different patient volumes between the two recruitment sites (Clinic 1 higher volume), and different recruitment strategies (Clinic 1 more efficient with a registry), we aimed to recruit approximately two thirds of participants from Clinic 1 and one third from Clinic 2, as well as ≥ 50 users and ≥ 50 non-users. We stopped recruitment when we reached our a priori goals.

All participants completed demographic and Screener and Opioid Assessment for Patients with Pain (SOAPP) questionnaires [15]. Demographic questions included age, education, income, employment, ethnicity, cigarette smoking, alcohol use, and recreational drug use. Information collected on pelvic pain history included self-reported rating of pelvic pain severity, presence of superficial and deep dyspareunia, years since diagnosis of MPP, other pelvic pain diagnoses, and use of medications for pelvic pain. The SOAPP questionnaire assessed risk of opioid abuse. Participants were asked “yes” or “no” questions to determine their cannabis use status.

We asked cannabis users to provide the following: age of first use, reason for using, frequency of use, duration of use, methods of consumption (smoking, vaporizing, oral, skin application, other), types of cannabis products (dried flower/leaf, edibles, liquid, cannabis vape pens/cartridges, topical products, concentrates, other), quantity of products, origin of products (licensed/unlicensed storefront, online store, self-grown, dealer), and average cost spent per month on cannabis. Users were asked to rate the effectiveness of cannabis for relieving pelvic pain, decreasing use of other pain medications, and impact on mood, sleep, social life, physical health, physical mobility, mental health, home life, work or studies, and quality of life. Some questions were inspired by the Canadian Cannabis Survey [16].

We asked non-cannabis users if they had ever used cannabis in the past. If applicable, we asked what they previously used cannabis for, and reasons for stopping. We also asked non-users whether they would be willing to use cannabis for pelvic pain, and if yes, how (methods of consumption, types of products, origins of products, cost per month). All participants were asked how likely (very unlikely, unlikely, likely, very likely) they would be to use each of the following products for pelvic

Table 1
Patient characteristics.

Variable	All (n = 135)	Non-users (n = 58)	Users (n = 77)	P
Age				< 0.001
Mean (SD)	38.2 (11.6)	44.5 (11.6)	33.5 (9.2)	
Range	(20.0, 73.0)	(24.0, 73.0)	(20.0, 64.0)	
Education – College or higher, n (%)	100 (74.1)	46 (79.3)	54 (70.1)	0.228
Ethnicity – white, n (%)	118 (87.4)	48 (82.8)	70 (90.9)	0.158
Annual household income, n (%)				0.040
Unknown	17	12	5	
< \$20,000	13 (11.0)	1 (2.2)	12 (16.7)	
\$20,000–\$39,999	19 (16.1)	7 (15.2)	12 (16.7)	
\$40,000–\$59,999	14 (11.9)	3 (6.5)	11 (15.3)	
\$60,000–\$79,999	22 (18.6)	11 (23.9)	11 (15.3)	
\$80,000 or more	50 (42.4)	24 (52.2)	26 (36.1)	
Current employment status, n (%)				0.025
Unknown	3	2	1	
Employed full time	62 (47.0)	34 (60.7)	28 (36.8)	
Employed part time/Self-employed	37 (28.0)	12 (21.4)	25 (32.9)	
Unemployed/Student/Retired/Other	33 (25.0)	10 (17.9)	23 (30.3)	
Current smoker, n (%)	14 (10.4)	4 (6.9)	10 (13.0)	0.251
Currently drink alcohol, n (%)	67 (49.6)	31 (53.4)	36 (46.8)	0.441
Years since diagnosis for pelvic pain/pelvic muscle spasm				0.046
Unknown, n	5	3	2	
Median (IQR)	5.0 (2.0, 10.0)	7.0 (4.0, 10.0)	4.0 (2.0, 8.0)	
Range	(0.0, 46.0)	(0.0, 46.0)	(0.0, 36.0)	
Other diagnoses, n (%)				
Endometriosis	97 (71.9)	33 (56.9)	64 (83.1)	0.001
Adenomyosis	15 (11.1)	8 (13.8)	7 (9.1)	0.389
Interstitial cystitis	12 (8.9)	5 (8.6)	7 (9.1)	0.924
Irritable bowel	36 (26.7)	8 (13.8)	28 (36.4)	0.003
Inflammatory bowel disease	8 (5.9)	3 (5.2)	5 (6.5)	1.000
Lower back injury	11 (8.1)	4 (6.9)	7 (9.1)	0.645
Hip injury	7 (5.2)	1 (1.7)	6 (7.8)	0.238
Other	21 (15.6)	10 (17.2)	11 (14.3)	0.639
Superficial dyspareunia, n (%)				0.005
Unknown	1	0	1	
No	51 (38.1)	15 (25.9)	36 (47.4)	
Yes	67 (50.0)	31 (53.4)	36 (47.4)	
Not sexually active	16 (11.9)	12 (20.7)	4 (5.3)	
Deep dyspareunia, n (%)				0.022
No	21 (15.6)	8 (13.8)	13 (16.9)	
Yes	98 (72.6)	38 (65.5)	60 (77.9)	
Not sexually active	16 (11.9)	12 (20.7)	4 (5.2)	
Current prescription medications for pain, n (%)				
Opioids	23 (17.0)	6 (10.3)	17 (22.1)	0.073
Anti-inflammatories	71 (52.6)	30 (51.7)	41 (53.2)	0.861
Muscle relaxants	19 (14.1)	8 (13.8)	11 (14.3)	0.935
Neuroleptics	23 (17.0)	8 (13.8)	15 (19.5)	0.384
Herbal medicine (not incl. cannabis)	18 (13.3)	4 (6.9)	14 (18.2)	0.056
Other	17 (12.6)	8 (13.8)	9 (11.7)	0.715
SOAPP total score > 4, n (%)	46/132 (34.8)	15/57 (26.3)	31/75 (41.3)	0.073
SOAPP total score				0.004
Unknown, n	3	1	2	
Mean (SD)	3.2 (2.0)	2.6 (1.5)	3.6 (2.2)	
Range	(0.0, 11.0)	(0.0, 6.0)	(0.0, 11.0)	

pain if available: cannabis vaginal suppositories, vaginal creams, and external vulvar creams.

We carried out a descriptive analysis to evaluate the current use and acceptability of use of cannabis in female patients with MPP. We also

compared demographics between cannabis users and non-users.

3. Results

We sent a total of 545 invitations and closed recruitment after receiving 135 complete questionnaire responses (Fig. A). 77 participants were cannabis users (57 %) and 58 were non-users (43 %). Differences in demographics, pelvic pain characteristics, and SOAPP scores between cannabis users and non-users are depicted in Table 1. The most common diagnosis associated with MPP in our cohort was endometriosis (71.9 %).

Among the 77 cannabis users, 61 (79.2 %), 38 (49.4 %), and 43 (55.8 %) reported using cannabis for pelvic pain, other medical reasons, and recreation respectively. Most users for pelvic pain (77 %) started using cannabis because conventional treatments did not work, 63.9 % desired more natural treatment options, and 32.8 % were influenced by recommendations from others who had tried cannabis for pelvic pain. 48.1 % used cannabis daily, while 18.3 % reported using less than once a week. Most used products for pelvic pain were dried cannabis flowers/leaves (68.9 %), edibles (60.7 %), and topicals (54.1 %). A small proportion of patients used CBD only or THC only products for pelvic pain (8.2 % and 1.6 % respectively). 86.9 % used products containing both CBD and THC. Evening (19:00–23:00) was the most common (82 %) time of day patients used cannabis for pelvic pain, however 31.1 % of patients reported using cannabis during the morning (06:00–10:00). Users reported spending an average of \$126.3 Canadian dollars on cannabis for pelvic pain per month (median \$80; range \$0–\$800). 52.5 % of participants had been using cannabis to treat pelvic pain for more than 2 years.

Participants rated effects of cannabis positively. On a scale of 0 (totally ineffective) – 10 (totally effective), 68.9 % of users rated the effectiveness of cannabis as 7 or higher at relieving pelvic pain. They also noted improvements in mood (75.4 %), sleep (91.8 %), physical health (62.3 %), physical mobility (70.5 %), mental health (77.0 %), home life (67.2 %), and quality of life (96.7 %). 73.8 % of users reported decreasing their use of other pain medications after starting to use cannabis for pelvic pain. About a third (31.1%) of users reported ever experiencing adverse effects from using cannabis for pain, most commonly unwanted feelings of being high (36.8 %), decreased attention span (36.8 %), dizziness (26.3 %), and anxiety (26.3 %).

Of the 58 non-cannabis users, 37 (63.8 %) would be willing to use cannabis for pelvic pain. For those not willing, the most common concerns were lack of information (47.6 %) and unwanted side effects (42.9 %). Six non-users (28.6 %) reported that they did not think cannabis use for pelvic pain was appropriate. 56.9 % of non-users had previously used cannabis for any reason but stopped mainly because of loss of interest (54.5 %), unwanted side effects (30.3 %) or inefficacy (18.2 %). Non-users willing to use cannabis for pelvic pain were most interested in consuming it orally (86.1 %), and were more willing to use edible, liquid, and topical cannabis products over dried flowers/leaves and vaporizers. The average price per month non-users were willing to spend on cannabis for pelvic pain was \$83.10 Canadian dollars (median \$50, range \$0–\$300).

A large proportion of both cannabis users and non-users were willing to use gynecological cannabis products if available. Notably, 88.3 % of users and 72.9 % of non-users responded that they would be either likely or very likely to use a vaginal cannabis insert. 75.4 % of users and 75.6 % of non-users responded that they would be willing to use an internal vaginal cannabis cream. Finally, 82.9 % of users and 83.4 % of non-users responded that they would be willing to use an external vulvar cannabis cream (Fig. B).

4. Discussion

Our cross-sectional study provides a comprehensive description of cannabis use and willingness to use patterns in myofascial pelvic pain




Fig. B. Willingness to use gynecological cannabis products if available.

patients for the broader research community. Most users turned to cannabis due to lack of effectiveness of conventional treatments, indicating a need for development of new therapeutic modalities.

Given that patients with MPP have great difficulty with vulvovaginal touching because of symptoms of vestibulodynia and vaginismus, it is particularly important to explore their willingness to use topical therapies. 50 % and 73 % of our participants noted pain at the superficial and deep vagina during penetration respectively. Although some demographic differences existed between users and non-users in our study, the majority of both considered vaginal and vulvar topical cannabis acceptable for use. One third of cannabis users in our study reported negative side-effects. The frequency of side-effects ranges up to 84 % in prior surveys [23]. Almost half of non-users in our study cited possible side-effects as detractors to use, and 30 % of non-users who had previously tried cannabis stopped due to unwanted side-effects. Cannabis products with topical application may have fewer side-effects but are not currently available in Canada. This highlights a potential pharmacologic therapy option deserving of further research for patients with MPP.

The Canadian Cannabis Survey (CCS) is administered annually by Health Canada and explores cannabis use behaviors in the general population. It asks about cannabis use for both medical and recreational purposes but does not go into details of the medical conditions. Cannabis users in our study were significantly younger than non-users (by approximately a decade). This is consistent with CCS results showing the highest reported prevalence of use among young adults [16]. Cannabis users compared to non-users in our study were less likely to be employed full time and had lower annual household incomes, however there were no differences in levels of education achieved. In the general population, the CCS found that Canadians with high school education or less had greatest proportions of cannabis use compared to those with higher levels of education [16]. It is possible that in patients with pain, a higher level of education may encourage exploration of unconventional therapies, such as cannabis [17–19,24].

The characteristics of cannabis use by our study participants are consistent with those of medical cannabis users, which tend to differ from purely recreational users in the amount consumed, THC content, and form of ingestion. We recently described patterns of cannabis use in a cohort of medical cannabis users at a dispensary in Vancouver, BC, where individuals would be subject to many of the same regulatory and environmental conditions as those in the present study [20]. In the dispensary study, medical users reported similar patterns of use, including amount consumed (most using 3.5–7 g per week), method of ingestion (70 % smoking), THC content (most using a THC:CBD mix

and time of day (mostly 7–10 pm) [20]. These patterns of use are typical of medical cannabis users, where daily help is required and edibles provide a more sustained form of pain relief that can be supplemented by smoking/vaping for acutely; THC:CBD combinations offer the advantage of effective pain relief with reduced euphoric effects, while use in the evening minimizes impairment during days and can aid with sleep. Although oral consumption was the top choice of non-users willing to try cannabis, a larger proportion of non-users (77.8 % were interested in trying cannabis via skin application compared to 27.3 % of users. This may reflect an openness of non-users to try novel or less conventional cannabis products.

It is unknown whether chronic use of cannabis for MPP might predispose some users to a Cannabis Use Disorder, which is associated with neurobiological changes [21]. There is evidence for CB1 upregulation in the reward pathway of those who use opioids, supporting the role of the endocannabinoid system in opioid abuse [22]. However, the potential for cannabis use in those with MPP to lead to opioid use has never been studied. Users in our study had a significantly higher SOAPP score than non-users, indicating a higher likelihood of addiction to opioids (mean 3.6 vs 2.6, $p = 0.004$). However, both users and non-users had a mean SOAPP score below the cut-off of 4 (which has a sensitivity of 0.86 and positive likelihood ratio of 2.59 for opioid addiction). Additionally, 73.8 % of cannabis users in our study indicated they were able to decrease their use of other pain medications. This is a higher proportion when compared to male and female participants who completed the medical portion of the CCS (57 % decreased) and may indicate better effects of cannabis on MPP when compared with other types of pain, or sex differences in outcomes [16]. This is a notable finding in the current climate of crisis with respect to opioids and their addictive effects.

Only one third of non-users had adequate pain management without cannabis and one half of them needed more information before attempting use. Legalization did not necessarily eradicate the stigma associated with cannabis use for pain. Educational initiatives on safety, tolerability and efficacy are needed in this context.

Strengths of our study include having a representative sample of patients with MPP from two pelvic pain clinics with various underlying conditions across ages, and well as including a non-cannabis user comparison group. Limitations of our study include possible participation bias from cannabis users in responding to our study; we addressed this to the best of our ability with a priori methodology to recruit at least 50 cannabis users and 50 non-cannabis users. As with most survey studies, our study also includes possible non-response bias as we are unable hear from non-responders. This is important to keep in mind when applying

our results to the broader population of patients with MPP. Our study did not aim to establish prevalence but rather obtain a cross-sectional representation of details of use and willingness to use in a group of patients with MPP to inform further research. This was reflected in our recruitment goals. Moreover, willingness to disclose cannabis use remains low, with only 51 % of survey respondents more willing to publicly disclose in Canada post-legalization [16]. This causes inherent challenges for recruitment into cannabis use studies.

5. Conclusion

Many female patients are self-medicating with cannabis and ideally should be supported by rigorous pharmacological and clinical efficacy research. Our study provides detailed information about patient preferences with respect to cannabis products and informs further research into pharmacokinetics and the development of new therapeutic options which may be more acceptable and better tolerated. Finally, the potential for opioid use should be monitored in any future trial of cannabis in MPP.

Funding

D.A. Boyes Memorial Research Award, Vancouver, BC, Canada. ID #F20-00334.

Declaration of conflicts of interest

MG received the D.A. Boyes Memorial Research Award which partially funded this project. AB has received compensation related to his research through Emerald Health Therapeutics and Ascension Sciences. The other authors have no relevant conflicts of interest.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.eurox.2023.100192](https://doi.org/10.1016/j.eurox.2023.100192).

References

- [1] Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. *Obstet Gynecol* 1996;87(3):321–7. [https://doi.org/10.1016/0029-7844\(95\)00458-0](https://doi.org/10.1016/0029-7844(95)00458-0).
- [2] Manz J, Hyakutake M, Kelly E. Calling for openness to the study of cannabis use in chronic pelvic pain. *J Obstet Gynecol Can* 2020;43(5):611–3.
- [3] Ross V, Determan C, Hallisey A. Myofascial pelvic pain: an overlooked and treatable cause of chronic pelvic pain. *J Midwifery Women's Health* 2021;66(2):148–60.
- [4] Gyang A, Hartman M, Lamvu G. Musculoskeletal causes of chronic pelvic pain: what a gynecologist should know. *Obstet Gynecol* 2013;121:645–50.
- [5] Bo K, Frawley HC, Haylen BT, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. *Int Urogynecol J* 2017;28(2):191–213.
- [6] Meister MR, Sutcliffe S, Ghetti C, et al. Development of a standardized, reproducible screening examination for assessment of pelvic floor myofascial pain. *Am J Obstet Gynecol* 2019;220(3):255 e1–9.
- [7] Bonder JH, Chi M, Rispoli L. Myofascial pelvic pain and related disorders. *Phys Med Rehabil Clin N Am* 2017;28(3):501–15.
- [8] Karp BI, Tandon H, Vigil D, et al. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. *Int Urogynecol J* 2019;30(7):1071–81.
- [9] Aredo JV, Heyrana KJ, Karp BI, et al. Relating chronic pelvic pain and endometriosis to signs of sensitization and myofascial pain and dysfunction. *Semin Reprod Med* 2017;35(1):88–97.
- [10] Government of Canada. Canadian tobacco, alcohol and drugs survey (CTADS): summary of results for 2017. Available at (<https://www.canada.ca/en/health-canada/services/canadian-alcohol-drugs-survey/2017-summary.html>). [Accessed July 2021].
- [11] Johal H, Devji T, Chang Y, et al. Cannabinoids in chronic non-cancer pain: a systematic review and meta-analysis. *Clin Med Insights Arthritis Musculoskelet Disord* 2020;13.
- [12] Geoffrion R, Yang EC, Koenig NA, et al. Recreational cannabis use before and after legalization in women with pelvic pain. *Obstet Gynecol* 2021;137(1):91–9.
- [13] Han L, Alton K, Colwill AC, et al. Willingness to use cannabis for gynecological conditions: a national survey. *J Women's Health* 2021;30(3):438–44.
- [14] Johns C, Lachiewicz M. Cannabis for treatment of chronic pelvic pain: a survey of prevalence and effectiveness. *Obstet Gynecol* 2019;133:90S.
- [15] Yosef A, Allaire C, Williams C, et al. Multifactorial contributors to the severity of chronic pelvic pain in women. *Am J Obstet Gynecol* 2016;215(6):760.e1–760.e14.
- [16] Butler SF, Budman SH, Fernandez K, et al. Screener and opioid assessment measure for patients with chronic pain. *Pain* 2004;112(1–2):65–75.
- [17] Government of Canada. Canadian Cannabis survey 2020: summary. Available at (<https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2020-summary.html>). [Accessed July 2021].
- [18] Phan VT, Stratton P, Tandon HK, et al. Widespread myofascial dysfunction and sensitisation in women with endometriosis-associated chronic pelvic pain: a cross-sectional study. *Eur J Pain* 2021;25(4):831–40.
- [19] Vercellini P, Crosignani PG, Abbiati A, et al. The effect of surgery for symptomatic endometriosis: the other side of the story. *Hum Reprod Update* 2009;15:177–88.
- [20] Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. *Hum Reprod Update* 2011;17:327–46.
- [21] Yau JC, Yu SM, Panenka WJ, et al. Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. *BMC Psychiatry* 2019;19(1):335.
- [22] Zehra A, Burns J, Liu CK, et al. Cannabis addiction and the brain: a review. *Am Psychiatr Publ* 2019;17(2):169–82.
- [23] Wiese B, Wilson-Poe AR. Emerging evidence for cannabis' role in opioid use disorder. *Cannabis Cannabinoid Res* 2018;3(1):179–89.
- [24] Carrubba AR, Ebbert JO, Spaulding AC, et al. Use of cannabis for self-management of chronic pelvic pain. *J Women's Health* 2020;30(9):1344–51.